WBB Securities

WBB Securities is a leading investment management, investment banking, and equity research firm focused primarily in the life science niche.

[WBB Securities @wbbsec]

In his latest @forbeshealth article, Dr. Brozak explores why patient advocacy and transparency are essential to improving healthcare access and affordability. Healthcare Is Broken: A New Report Says Patient Advocacy Is The Answer via @forbes https://t.co/cgMoF1brML

[WBB Securities @wbbsec]

Medical innovation cannot be measured by scientific achievement alone. As new therapies transform what is possible, the challenge is ensuring that innovation, affordability, and patient access can advance together.

Read the full article:
https://t.co/eoPcrkFwLc

[WBB Securities @wbbsec]

New in @Forbes from Dr Steve Brozak: What Price Healthcare? RevMed’s Rasonque-The US Drug Pricing Paradox via @forbes https://t.co/eoPcrkFwLc
What should healthcare value: the price of a treatment or the long-term value it delivers to patients?
#Biotech #Healthcare #DrugPricing

[WBB Securities @wbbsec]

@Forbes article by Dr. Steve Brozak: What Fauci's Senate Testimony Hearing Can Teach Public Health Leaders.
A look at leadership, transparency, public trust, and scientific communication in public health.
Read more: https://t.co/RXGo9iAylJ

[WBB Securities @wbbsec]

Is biotechnology investing or speculation?
Dr Brozak's latest @Forbes article explores what Warren Buffett's warning about today's "gambling mood" in the markets means for biotech investors and why disciplined analysis still matters.
https://t.co/rNmp8KYyYc

[WBB Securities @wbbsec]

🚨 Tomorrow at 11:00 AM ET. How can we advance biotechnology while protecting against future biological risks?
Join Steven Quay, MD, PhD, and Nicholas Wade for:
"New Guardrails Required for Today's Pathogen Biology"
Register: https://t.co/IZ6ejOc9Dx
#Biotech #Healthcare

[WBB Securities @wbbsec]

How do we make pathogen research safer without slowing development? Former @nytimes science editor Nicholas Wade talks with Steven Quay, MD PhD, on the guardrails today's biology needs. Free virtual salon, Wed June 17 @ 11AM EST, live Q&A. Register https://t.co/IZ6ejOc9Dx

[WBB Securities @wbbsec]

In @forbeshealth, Dr. Steve Brozak reviews Steven Quay's The Code As Witness, laying out 5 "smoking gun" traits behind the case for Covid-19's lab origins and why institutional secrecy leaves us unprepared for the next pandemic. Read here: https://t.co/YlNrMHuXVO

[WBB Securities @wbbsec]

Why is the 2026 Ebola outbreak raising new concerns?
Dr. Steve Brozak examines institutional distrust, attacks on healthcare infrastructure, delayed containment efforts, and global preparedness. Read here via @forbes https://t.co/McE5yetLF2 #Ebola #GlobalHealth

[WBB Securities @wbbsec]

A WHO emergency meeting. Multiple countries monitoring cases. Questions about transmission, preparedness, and containment. In @forbeshealth, Dr. Steve Brozak examines 5 urgent questions emerging from the recent Hantavirus outbreak. Read here: https://t.co/04yzeRLOUZ #Hantavirus

[WBB Securities @wbbsec]

Steve Brozak examines HHS Secretary Robert F. Kennedy Jr.’s focus on the mental health crisis and psychiatric overprescribing and what can be done moving forward. "Our Mental Health Crisis: RFK Jr. Faces Psychiatric Over-Prescribing" via @forbes https://t.co/60vwK9jopQ

[WBB Securities @wbbsec]

WBB Sec President Dr Steve Brozak is moderating today’s #BiotechShowcase panel: “Working with ARPA-H: Federal Investment in Biotech & Healthcare Innovation.”
Featuring ARPA-H leaders:
Dr Jessica Green, Natalie Kates & Dr Paul Sheehan.

🔗 https://t.co/THDPr9fRjU #BiotechShowcase

[WBB Securities @wbbsec]

The US healthcare system faces a real stress test in 2026. In @Forbes, Dr Brozak examines how the potential ACA subsidy cliff exposes deeper structural risks in healthcare’s business model, from incentives to access to rising costs. Read more via @forbes https://t.co/Wctv9o5s7n

[WBB Securities @wbbsec]

OYE Therapeutics raises $5.475M Series A to advance high-concentration caffeine therapy for anesthesia recovery & OIRD. WBB Securities acted as placement agent. Phase 1 planned for Q1 2026. Congrats to the OYE team on reaching this important milestone.
🔗https://t.co/nSig6qywW8

[WBB Securities @wbbsec]

Dr. Brozak describes why it’s critical to understand the role that Medicaid and Medicaid State-directed payments (SDPs) play in the survival of what are known as Safety Net Hospitals and the entire US Healthcare System. Via @Forbes https://t.co/UJFC0vTjUF

[WBB Securities @wbbsec]

WBB Securities acted as sole placement agent in #FELIQSCorp’s $9M Series A to advance FLQ-101, a novel treatment to prevent blindness in premature infants. #Biotech #ROP
🔗 https://t.co/potWMYigb7

[Sara Jane Demy @demy_sara]

🎉 💬 We’re hosting our 50th complimentary #VirtualSalon w/a timely discussion on CD19 CAR-T therapies & their impact since @US_FDA approval. I would love for you to join us on May 28, from 11:00 AM – 12:00 PM ET.

👉 Complimentary registration: https://t.co/3ZOZEGwZCs

[WBB Securities @wbbsec]

Seven years after the FDA's first approval, what have we learned about #CellTherapy and #GeneTherapy?

Join the conversation at the @DemyColton Virtual Salon
🔗 https://t.co/9G8yQdsvDG
#Biotech #FDA #Innovation #LifeSciences #WBB

[WBB Securities @wbbsec]

President Donald Trump – Will He Become The Drug Price Equalizer? via @forbes by Dr. Steve Brozak, WBB Sec. – Why US drugs are the world’s costliest and how Most Favored Nation will affect the pharma industry. https://t.co/fsAI3x2Gki

[WBB Securities @wbbsec]

Tariffs on pharmaceuticals could reshape the industry. In his latest @Forbes article, Dr. Steve Brozak examines how the U.S. dodged a bullet—for now. But can domestic manufacturing step up? Read more: https://t.co/Fly3m9dx39 #Pharma #Biotech #Healthcare #DrugShortages #Forbes